Last reviewed · How we verify
RP followed by MPR
RP followed by MPR is a Small molecule drug developed by Fondazione EMN Italy Onlus. It is currently in Phase 2 development. Also known as: Revlimid, Prednisone, Melphalan.
At a glance
| Generic name | RP followed by MPR |
|---|---|
| Also known as | Revlimid, Prednisone, Melphalan |
| Sponsor | Fondazione EMN Italy Onlus |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Revlimid And Prednisone Followed By Revlimid, Melphalan And Prednisone In Multiple Myeloma Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RP followed by MPR CI brief — competitive landscape report
- RP followed by MPR updates RSS · CI watch RSS
- Fondazione EMN Italy Onlus portfolio CI
Frequently asked questions about RP followed by MPR
What is RP followed by MPR?
RP followed by MPR is a Small molecule drug developed by Fondazione EMN Italy Onlus.
Who makes RP followed by MPR?
RP followed by MPR is developed by Fondazione EMN Italy Onlus (see full Fondazione EMN Italy Onlus pipeline at /company/fondazione-emn-italy-onlus).
Is RP followed by MPR also known as anything else?
RP followed by MPR is also known as Revlimid, Prednisone, Melphalan.
What development phase is RP followed by MPR in?
RP followed by MPR is in Phase 2.
Related
- Manufacturer: Fondazione EMN Italy Onlus — full pipeline
- Also known as: Revlimid, Prednisone, Melphalan
- Compare: RP followed by MPR vs similar drugs
- Pricing: RP followed by MPR cost, discount & access